Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector78910.54101/ACEN.2022.4.7ReviewsОбзорыReview ArticleMultiple system atrophy: diagnostic methods and biomarkersМультисистемная атрофия: методы диагностики и биомаркерыhttps://orcid.org/0000-0002-3718-6238AndreevMaksim N.АндреевМаксим Николаевич
Russian Federation

postgraduate student, 5th Neurology department

аспирант 5-го неврологического отд.

max_andreev@mail.ruhttps://orcid.org/0000-0001-8070-7644FedotovaEkaterina Yu.ФедотоваЕкатерина Юрьевна
Russian Federation

D. Sci. (Med.), leading researcher, Head, 5th Neurology department

д.м.н., в.н.с., зав. 5-м неврологическим отделением

ekfedotova@neurology.ruResearch Center of NeurologyФГБНУ «Научный центр неврологии»2312202216454610612202131012022Copyright ©; 2022, Andreev M.N., Fedotova E.Y.Copyright ©; 2022, Андреев М.Н., Федотова Е.Ю.2022Andreev M.N., Fedotova E.Y.Андреев М.Н., Федотова Е.Ю.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/789

Multiple system atrophy (MSA) is a neurodegenerative disease belonging to a group of synucleinopathies and characterized by significant autonomic failure, parkinsonian syndrome, and cerebellar signs. Diagnostic criteria used currently were updated in 2022. While the clinical method and neuroimaging are typically diagnostic in MSA, new modalities are currently emerging. Novel candidate biomarkers are being intensively and thoroughly studied.

The review analyzes the clinical picture and diagnostic criteria of the disease, describes imaging methods for diagnosing synucleinopathies, as well as known laboratory markers of multiple system atrophy.

Мультисистемная атрофия — нейродегенеративное заболевание из группы синуклеинопатий, характеризующееся выраженной недостаточностью вегетативной нервной системы в сочетании с синдромом паркинсонизма и мозжечковыми нарушениями. Диагностические критерии заболевания, применяемые в настоящее время, обновлены в 2022 г. Для диагностики мультисистемной атрофии в основном применяются клинический и нейровизуализационный методы, однако спектр диагностических вмешательств в последнее время расширяется, активно исследуются новые кандидаты на роль биомаркеров заболевания.

В обзоре проанализированы клиническая картина и диагностические критерии заболевания, описаны визуализационные методы диагностики синуклеинопатий, а также известные лабораторные маркеры мультисистемной атрофии.

multiple system atrophyparkinsonismbiomarkersdiagnosisсинуклеинопатиямультисистемная атрофияпаркинсонизмбиомаркерыдиагностикаFanciulli A., Wenning G.K. Multiple-system atrophy. New Engl. J. Med. 2015; 372(3): 249–263. DOI: 10.1056/NEJMra1311488Jellinger K.A. Multiple system atrophy: An oligodendroglioneural synucleinopathy. J. Alzheimer’s Dis. 2018; 62(3): 1141–1179. DOI: 10.3233/JAD-170397Bjornsdottir A., Gudmundsson G., Blondal H., Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J. Neurol. Neurosurg. Psychiatry. 2013; 84(2): 136–140. DOI: 10.1136/jnnp-2012-302500Palma J.A., Norcliffe-Kaufmann L., Kaufmann H. Diagnosis of multiple system atrophy. Auton. Neurosci. 2018; 211: 15–25. DOI: 10.1016/j.autneu.2017.10.007Coon E.A., Singer W., Low P.A. Pure autonomic failure. Mayo Clin. Proc. 2019; 94(10): 2087–2098. DOI: 10.1016/j.mayocp.2019.03.009Koga S., Sekiya H., Kondru N. et al. Neuropathology and molecular diagnosis of Synucleinopathies. Mol. Neurodegenerat. 2021; 16(1): 83. DOI: 10.1186/s13024-021-00501-zWenning G.K., Stankovic I., Vignatelli L. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov. Disord. 2022; 37(6): 1131–1148. DOI: 10.1002/mds.29005Köllensperger M., Geser F., Seppi K. et al. Red flags for multiple system atrophy. Mov. Disord. 2008; 23(8): 1093–1099. DOI: 10.1002/mds.21992Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996; 46(5): 1470–1470. DOI: 10.1212/wnl.46.5.1470Mendoza-Velásquez J.J., Flores-Vázquez J.F., Barrón-Velázquez E. et al. Autonomic dysfunction in α-synucleinopathies. Front. Neurol. 2019; 10: 363. DOI: 10.3389/fneur.2019.00363Ewing D.J., Martyn C.N., Young R.J., Clarke B. F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8(5): 491–498. DOI: 10.2337/diacare.8.5.491Baschieri F., Calandra-Buonaura G., Doria A. et al. Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. Parkinsonism Relat. Disord. 2015; 21(5). C: 477–482. DOI: 10.1016/j.parkreldis.2015.02.011Fanciulli A., Jordan J., Biaggioni I. et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin. Autonom. Res. 2018; 28(4): 355–362. DOI: 10.1007/s10286-018-0529-8Vernino S., Low P.A. Autonomic Neuropathies. Elsevier, 2007: 979–986. DOI: 10.1016/B978-012088592-3/50091-8Coon E., Fealey R.D., Sletten D.M. et al. Anhidrosis in multiple system atrophy involves pre- and postganglionic sudomotor dysfunction. Mov. Disord. 2017; 32(3): 397–404. DOI: 10.1002/mds.26864Iodice V., Lipp A., Ahlskog J.E. et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J. Neurol. Neurosurg. Psychiatry. 2012; 83(4): 453–459. DOI: 10.1136/jnnp-2011-301068Nojszewska M., Potulska-Chromik A., Jamrozik Z. et al. Electrophysiolo- gical and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. Neurol. Neurochir. Polska. 2019; 53(1): 26–33. DOI: 10.5603/PJNNS.a2019.0005Shindo K., Fukao T., Kurita N. et al. Sympathetic outflow to skin predicts central autonomic dysfunction in multiple system atrophy. Neurol. Sci. 2020. 41(8): 2241–2248. DOI: 10.1007/s10072-020-04340-6Bloch F., Pichon B., Bonnet A.M. et al. Urodynamic analysis in multiple system atrophy: Characterisation of detrusor-sphincter dyssynergia. J. Neurol. 2010; 257(12): 1986–1991. DOI: 10.1007/s00415-010-5645-xKim M., Jung J.H., Park J. et al. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson’s disease. Parkinsonism Relat. Disord. 2015; 21(3): 205–210. DOI: 10.1016/j.parkreldis.2014.12.003Xing T., Ma J., Jia C., Ou T. Neurogenic lower urinary tract dysfunction predicts prognosis in patients with multiple system atrophy. Clin. Auton. Res. 2020; 30(3): 247–254. DOI: 10.1007/s10286-020-00678-1Hahn K., Ebersbach G. Sonographic assessment of urinary in multiple system atrophy and idiopathic Parkinson’s disease. Mov. Disord. 2005; 20(11): 1499–1502. DOI: 10.1002/mds.20586Krismer F., Pinter B., Mueller C. et al. Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat. Disord. 2017; 35: 36–41. DOI: 10.1016/j.parkreldis.2016.11.010Xia C., Postuma R.B. Diagnosing multiple system atrophy at the prodromal stage. Clin. Auton. Res. 2020; 30(3): 197–205. DOI: 10.1007/s10286-020-00682-5Palma J.A., Fernandez-Cordon C., Coon E.A. et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin. Autonom. Res. 2015; 25(1): 69–75. DOI: 10.1007/s10286-015-0279-9Cortelli P., Calandra-Buonaura G., Benarroch E.E. et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019; 93(14): 630–639. DOI: 10.1212/WNL.0000000000008208Gandor F., Vogel A., Claus I. et al. Laryngeal movement disorders in multiple system atrophy: a diagnostic biomarker? Mov. Disord. 2020; 35(12): 2174–2183. DOI: 10.1002/mds.28220Warnecke T., Vogel A., Ahring S. et al. The shaking palsy of the larynx — potential biomarker for multiple system atrophy: a pilot study and literature review. Front. Neurol. 2019; 10: 1–12. DOI: 10.3389/fneur.2019.00241Gilman S., Wenning G.K., Low P.A. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9): 670–676. DOI: 10.1212/01.wnl.0000324625.00404.15Bajaj S., Krismer F., Palma J. et al. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: a systematic review and meta-analysis. PLoS ONE. 2017; 12(12): e0189897. DOI: 10.1371/journal.pone.0189897Kim M., Ahn J.H., Cho Y. et al. Differential value of brain magnetic resonance imaging in multiple system atrophy cerebellar phenotype and spinocerebellar ataxias. Sci. Rep. 2019; 9(1): 1–7. DOI: 10.1038/s41598-019-53980-yBeliveau V., Krismer F., Skalla E. et al. Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. Parkinsonism Relat. Disord. 2021; 85: 30–36. DOI: 10.1016/j.parkreldis.2021.02.027Krismer F., Seppi K., Göbel G. et al. Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. Mov. Disord. 2019; 34(7): 1041–1048. DOI: 10.1002/mds.27669Kadodwala V.H., Hadjivassiliou M., Currie S. et al. Is 1H-MR spectroscopy useful as a diagnostic aid in MSA-C? Cerebellum Ataxias. 2019; 6(1): 1–8. DOI: 10.1186/s40673-019-0099-0Chandran V., Stoessl A.J. Imaging in multiple system atrophy. Neurol. Clin. Neurosci. 2014; 2(6): 178–187. DOI: 10.1111/ncn3.125Thobois S., Prange S., Scheiber C., Broussolle E. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: a practical perspective. Parkinsonism Relat. Disord. 2019; 59: 93–100. DOI: 10.1016/j.parkreldis.2018.08.016Zhou H.Y., Huang P., Sun Q. et al. The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy. Transl. Neurodegener. 2018; 7(1): 1–7. DOI: 10.1186/s40035-018-0121-0Федотова Е.Ю., Чечеткин А.О., Иллариошкин С.Н. Возможности транскраниальной сонографии в диагностике экстрапирамидных заболеваний. Анналы клинической и экспериментальной неврологии. 2010; 4(4): 43–50. Fedotova E.Yu., Chechetkin A.O., Illarioshkin S.N. Possibilities of transcranial sonography in extrapyramidal disorders Annals of Clinical and Experimental Neurology. 2010; 4(4): 43–50. (In Russ.)Cong S., Xiang C., Wang H., Cong S. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. J. Neurol. 2021; 268: 2703–2712. DOI: 10.1007/s00415-020-09781-9Laurens B., Constantinescu R., Freeman R. et al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol. Dis. 2015; 80: 29–41. DOI: 10.1016/j.nbd.2015.05.004Bungeroth M., Appenzeller S., Regulin A. et al. Differential aggregation properties of alpha-synuclein isoforms. Neurobiol. Aging. 2014; 35(8): 1913–1919. DOI: 10.1016/j.neurobiolaging.2014.02.009Brudek T., Winge K., Rasmussen N.B. et al. Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains. J. Neurochem. 2016; 136(1): 172–185. DOI: 10.1111/jnc.13392Miglis M.G., Larsen N., Muppidi S. RT-QUiC in multiple system atrophy: the biomarker of the future? and other updates on recent autonomic research. Clin. Autonomic Res. 2021; 31(1): 47–49. DOI: 10.1007/s10286-021-00767-9Rumund A. van, Green A.J.E., Fairfoul G. et al. α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann. Neurol. 2019; 85(5): 777–781. DOI: 10.1002/ana.25447Shahnawaz M., Mukherjee A., Pritzkow S. et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020; 578(7794): 273–277. DOI: 10.1038/s41586-020-1984-7Ge F., Ding J., Liu Y. et al. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: a meta-analysis. Neurosci. Lett. 2018; 685: 35–41. DOI: 10.1016/j.neulet.2018.07.030Hu X., Yang Y., Gong D. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis. Neurol. Sci. 2017; 38(3): 407–414. DOI: 10.1007/s10072-016-2783-7Palleis C., Morenas-Rodriguez E., Murcia F.J.M. et al. Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clin. Neurol. and Neurosurg. 2020; 195: 105924. DOI: 10.1016/j.clineuro.2020.105924Wang Y., Wei X., Zou J. et al. Contra-directional expression of serum homocysteine and uric acid as important biomarkers of multiple system atrophy severity: a cross-sectional study. Front. Cell Neurosci. 2015; 9: 1–11. DOI: 10.3389/fncel.2015.00247Abraham A., Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J. Neurol. 2014; 261(6): 1133–1138. DOI: 10.1007/s00415-014-7331-xZhang X., Liu D.S., An C.Y. et al. Association between serum uric acid level and multiple system atrophy: a meta-analysis. Clin. Neurol. Neurosurg. 2018; 169: 16–20. DOI: 10.1016/j.clineuro.2018.03.023Monzio Compagnoni G., Fonzo A. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathol. Commun. 2019; 7(1): 113. DOI: 10.1186/s40478-019-0730-6Compta Y., Giraldo D.M., Muñoz E. et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism Relat. Disord. 2018; 46: 16–23. DOI: 10.1016/j.parkreldis.2017.10.010Kasai T., Tokuda T., Ohmichi T. et al. Serum levels of coenzyme Q10 in patients with multiple system atrophy. PLoS ONE. 2016; 11(1): 1–7. DOI: 10.1371/journal.pone.0147574Mitsui J., Matsukawa T., Yasuda T. et al. Plasma coenzyme Q10 levels in patients with multiple system atrophy. JAMA Neurol. 2016; 73(8): 977–980. DOI: 10.1001/jamaneurol.2016.1325Donadio V., Incensi A., El-Agnaf O. et al. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Sci. Rep. 2018; 8(1): 14246. DOI: 10.1038/s41598-018-32588-8Donadio V., Incensi A., Rizzo G. et al. Skin biopsy may help to distinguish multiple system atrophy–Parkinsonism from Parkinson’s disease with orthostatic hypotension. Mov. Disord. 2020; 35(9): 1649–1657. DOI: 10.1002/mds.28126Miglis M.G., Muppidi S. Can skin biopsy differentiate Parkinson disease from multiple system atrophy? And other updates on recent autonomic research. Clin. Autonomic Res. 2020; 30(4): 287–289. DOI: 10.1007/s10286-020-00712-2